Publication | Closed Access

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome

ObesityMetabolic SyndromeImmunoreactive Insulin LevelsMedicineInsulin ManagementDiabetesPathologyGynecologyPolycystic Ovary SyndromeHyperlipidemiaMetformin TherapyEndocrinologyPharmacologyInsulin SignalingWomen's HealthOvarian CancerHealth Sciences